Over five million people in the UK are currently receiving treatment for asthma and the NHS spends over £1 billion each year treating the condition.01The economic and societal burden of respiratory conditions weigh heavily on healthcare services.

5.4 million people in the UK 01 and 300 million people globally - equivalent to almost the entire population of the USA - suffer from asthma. 02 Chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), kill more than four million people every year and affect hundreds of millions more.02 

Respiratory medicines from Teva

Teva has several innovative branded medicines that treat respiratory diseases and conditions such as asthma, cystic fibrosis and Chronic Obstructive Pulmonary Disease (COPD) and we’re developing e-connected devices to help improve patient compliance with their prescribed medication.

To learn more about Teva's medicines and their availability in the UK, or to speak to a Medical Affairs professional from Teva please contact us.


As well as developing and providing our own specialty medicines dedicated to the treatment of asthma, COPD and Cystic Fibrosis, we provide a range of information, consultation and education services to help you manage and improve the service you provide to your patients. This includes inhaler technique training and helping patients understand how compliance and self management of their condition can benefit their overall health.

Collaborative working with the NHS

We focus on supporting the NHS in managing long-term conditions like asthma and chronic obstructive pulmonary disease (COPD). We address cost-efficient prescribing and develop joined-up care through our collaborative working partnerships to help improve patient outcomes and also offer value for money. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.

Learn more


Teva's research in Respiratory

Applying expertise, innovation and technology to improve health

Our research and development teams are working on solutions to address unmet needs in respiratory medicine and we have a promising pipeline of treatments. 

The focus of our research efforts in respiratory is on breath-activated inhaled therapies for asthma and COPD, where incorrect inhaler technique and non-adherence has been shown to be associated with poor asthma control, as well as targeted biologics for uncontrolled asthma.


Smart Inhaler Technology

A key area our global research teams are focusing on is E-connectivity. Using smart inhaler technology patients may be more empowered to manage their condition more effectively, and healthcare professionals could obtain greater insight into the patient's experience and condition to make more informed treatment decisions.

One of our solutions is a hardware device that attaches to select metered-dose inhalers, as well as a software programme which synchronises and stores data through an app-based user interface. This gives both patients and clinicians a clear view of the asthma symptoms and how their treatment could be modified, if necessary.

This could empower patients and carers to understand, monitor and manage their health - and could enable healthcare professionals to make data-driven decisions about identifying high risk patients, improving quality of life and better co-ordinating care delivery to optimise resource allocation and reduce costs.



We are dedicated to supporting our patients and healthcare professionals

Our experience in respiratory means we are well placed to invest in extensive research into medicines to help alleviate the many symptoms of asthma, cystic fibrosis and COPD, to offer patients and healthcare professionals a wider choice of treatments, and to support patients along their treatment path.

Life Effects™ - patient support from Teva

Chronic illness can turn life upside down

Poor health impacts life in so many different ways—physically, mentally, emotionally, socially and financially, to name a few. Through Teva’s Life Effects™ website patients and caregivers share their tips and real life experiences to help other patients navigate their new normal.

Life Effects™ for patients

The only people who really understand the patient experience is other patients
Read their stories

Life Effects™ for caregivers

Navigating the challenges and joys of caregiving
Learn from other caregivers

Supporting Healthcare Professionals
dedicated to Respiratory

Teva provides Let’s Talk Respiratory website - a free to access online hub of educational materials
and resources, providing the latest news and updates supporting medical education in asthma,
cystic fibrosis and COPD.

Healthcare professionals can access resources that they can use with patients to help manage their 
conditions, such as asthma and COPD patient booklets and consultation guides, self-management
plans and peak flow diaries.

Let’s Talk Respiratory

A respiratory hub for healthcare professionals supporting medical education in asthma, cystic fibrosis and COPD

Learn more Let’s Talk Respiratory

Medical Affairs

Teva’s Medical Affairs team is responsible for providing medical support to our company
(both branded and generics), and for interacting with external customers through medical
information and medical education.

The goal of Medical Affairs is to advance our medical knowledge in key therapeutic areas,
including neurological disorders, oncology, pain management and respiratory diseases.
The team supports patients and healthcare professionals by providing medical
information, scientific communications and educational activities.

Medical Affairs ensures that healthcare professionals are well informed about the safety
and efficacy profile of Teva’s products to support the proper use of our medicines and devices.

Medical Affairs Contact Information

E-mail Telephone


Read more


Read more

Consumer Health

Read more

Central Nervous System

Read more


  1. Back to contents.
  2. Back to contents.

    World Health Organisation - Accessed August 2021

Date of preparation: August 2021
Reference: COB-GB-NP-00075